海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.
- Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with 1 to 4 packed red blood cell units per 8-week period) ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Belgium, Brazil, Germany, Israel, Italy, Korea, Republic of, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom, United States
- 2017-08-18
Authorised
- Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.
- Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with 1 to 4 packed red blood cell units per 8-week period);Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom, United States
- 2017-08-08
Authorised
- Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.
- Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with 1 to 4 packed red blood cell units per 8-week period) ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom, United States
- 2017-07-31
Authorised
- A study of REGN2810 (Cemiplimab, Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy versus pembrolizumab in patients with lung cancer
- Non-Small Cell Lung Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Serbia, Slovakia, South Africa, Sweden, Switzerland, United Kingdom, United States
- 2018-04-17
Authorised
- A study of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy versus pembrolizumab in patients with lung cancer
- Non-Small Cell Lung Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Serbia, Slovakia, South Africa, Sweden, Switzerland, United Kingdom, United States
- 2018-03-08
Authorised
- A clinical study comparing 2 different strategies for management of subjects with Plaque Psoriasis who have responded to Etanercept treatment
- Plaque psoriasis MedDRA version: 14.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- France, Germany, Greece, Hungary, Italy, Portugal, Spain, Turkey, United Arab Emirates, United Kingdom
- 2009-09-24
Authorised
- A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years
- Symptomatic nonerosive GERD in paediatric subjects aged 1 to 11 years MedDRA version: 18.1 Level: LLT Classification code 10066874 Term: Gastroesophageal reflux disease System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium, Brazil, Israel, Italy, Mexico, Poland, Portugal, United States
- 2015-10-23
Authorised
- Study to evaluate safety and effectiveness of NA-1 in reducing disability in stroke patients selected for mechanical clot removal procedures.
- Acute Ischemic Stroke (AIS) in adult subjects with a large intracranial arterial occlusion, a small ischemic core, and good collaterals. MedDRA version: 20.0 Level: PT Classification code 10061256 Term: Ischaemic stroke System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10055221 Term: Ischemic stroke System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10023027 Term: Ischaemic stroke NOS System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10074321 Term: Nonhaemorrhagic stroke System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10074318 Term: Nonhemorrhagic stroke System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Canada, Germany, Ireland, Korea, Republic of, Sweden, United Kingdom, United States
- 2017-12-18
Authorised
- A multiphase study assessing the anti-tumor activity and safety of JNJ-63723283 (an Anti-PD-1 monoclonal antibody) administered in combination with daratumumab, compared with daratumumab alone in subjects with relapsed or refractory Multiple Myeloma.
- Relapsed or Refractory Multiple Myeloma (MM). MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000054086 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, France, Germany, Greece, Israel, Russian Federation, Spain, Turkey, United States
- 2017-08-04
Authorised
- Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetes
- Diabetes Mellitus, Type 1 MedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Australia, Austria, Brazil, Canada, Denmark, European Union, Greece, Ireland, Israel, Russian Federation, Serbia, Spain, United Kingdom
- 2017-07-19